The Latest Breaking News from diabetes

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro should drive the biopharma stock much higher, said a Morgan Stanley analyst.

Researchers believe that if patients who are likely to respond well to antiseptic mouthwash could be identified, it would be an easy-to-use treatment for people with periodontic-linked diseases.

Two of the most frequent pregnancy-problems">pregnancy problems are hypertensive disorders of pregnancy (HDP) and gestational diabetes (GDM), which increase pregnant people's risk of developing cardiovascular disease later in life. Read further on Dynamite News:

The FDA issues warnings to online vendors selling misbranded weight-loss and diabetes drugs, highlighting potential health risks and illegal practices.

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

The prevalence of diabetes increased from 10.3% of people in 2001 to 11.6% in 2021.

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Type 2 diabetes is related to an increased risk of kidney stones; however, various forms of treatment for this condition may potentially reduce the risk of kidney stones. Read further on Dynamite News:

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.